TNON Earnings Prediction
The chart below shows how TNON performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TNON sees a -16.39% change in stock price 10 days leading up to the earnings, and a -22.27% change 10 days following the report. On the earnings day itself, the stock moves by +4.01%. This data can give you a slight idea of what to expect for the next quarter's release.
TNON Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
887.00K
-6.04%
-1.55%
Gross Margin
47.13%
-16.83%
-9.64%
Operating Margin
-362.46%
1.29%
-15.66%
Net Margin
-358.96%
1.70%
-15.47%
EPS
-3.63
-69.00%
-55.51%
No Data Available
TNON Earnings Analysis
Tenon Medical, Inc. Common Stock Corporation (TNON.O) Earnings Conference Call
Positive
Revenue Increase Analysis: 1. Year-over-Year Revenue Growth: Tenon Medical achieved an 18% increase in revenue for the nine months ended September 30, 2024, rising to $2.5 million compared to $2.1 million in the prior year period.
Gross Margin Improvement: 2. Improved Gross Margin: The gross margin improved significantly by 2,200 basis points to 54% for the nine months ended September 30, 2024, compared to 32% in the same period last year.
Capital Raise Success: 3. Successful Capital Raise: The company secured net proceeds of approximately $9.6 million during the third quarter of 2024 through an investment and additional equity financings, strengthening its balance sheet for growth initiatives.
Strong Market Potential: 4. Positive Clinical Feedback: Initial clinical procedures with the new Catamaran SE received extremely positive feedback from physician advisors, indicating strong market potential ahead of its full commercial launch planned for early 2025.
Patent Issuance Impact: 5. Patent Protection: The U.S. Patent Office issued three new patents related to the Catamaran prosthesis, enhancing the company's competitive position and protecting its innovative technology in the market.
Negative
Revenue Decline Analysis: During the third quarter, revenue declined 6% over the prior year quarter and 1.6% over the second quarter of 2024, primarily due to unexpected reimbursement per authorization headwinds.
Quarterly Revenue Decline: Revenue for the third quarter of 2024 was $887,000, a decrease of 6% compared to $944,000 in the third quarter of 2023.
Gross Profit Comparison Q3: Gross profit in the third quarter of 2024 was $418,000, or 47% of revenue, compared to $535,000 or 57% of revenue in the third quarter of 2023.
Net Loss Improvement: Net loss was $3.2 million for the third quarter of 2024, an improvement from a net loss of $3.3 million in the same period in 2023, but the company expects to incur additional losses in the future.
Operating Expenses Decrease: Operating expenses totaled $3.6 million for the third quarter of 2024, a decrease from $3.9 million in the third quarter of 2023, but still significant in relation to revenue.
TNON FAQs
How does TNON typically perform around its earnings report dates?
Is Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TNON Earning Call Sentiment
Tenon Medical, Inc. (TNON) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TNON.O
-3.6%Positive
The earnings call presents a mixed sentiment. While there are positive aspects like cash position, no debt, and increased surgical procedures, there are concerns over revenue decline, reimbursement issues, and anticipated losses. The Q&A section reveals some uncertainty in management's responses, particularly regarding reimbursement challenges. Despite some positive developments, such as physician feedback-driven product updates and sales force expansion, the overall sentiment remains neutral due to the balance of positive and negative factors.
